8 August 2014 - Deborah Wilkes
Get up to speed with Meda's OTC strategy following the news that the Swedish company is acquiring Italy's Rottapharm Madaus in a deal worth SEK21.2 billion (US$3.08 billion).
This NEWS EXTRA publication from OTCToolbox will give you a rapid and detailed insight into the deal announced on 31 July 2014. The transaction will boost Meda's OTC business with a portfolio of established non-prescription brands, increase the Swedish company's total sales by around 40%, and double its sales in emerging markets. Following completion of the deal, Meda will have a consumer healthcare business with annual sales of around US$1 billion.
The publication provides details of Meda's OTC strategy over the past four years, which has seen the specialty pharma company steadily build its OTC business through a string of acquisitions in the US and Europe. It also covers the company's financial performance and fight to remain independent.
Around 3,000 words long, the NEWS EXTRA provides an overview of privately-owned Rottapharm Madaus, including its leading products. It also looks at the Italian company's failed Initial Public Offering (IPO).
This NEWS EXTRA – entitled 'Meda boosts OTC with Rottapharm Madaus deal' – is available to purchase and download immediately from the OTCToolbox website. You can make sure your team is well informed through a Multiple User Licence or a Global Licence.
RAPID INSIGHTS MADE EASY
AVAILABLE TO DOWNLOAD IMMEDIATELY AS A PDF
See Payment Options box on this page
This NEWS EXTRA is also available as part of an Annual Subscription to the OTCToolbox website (click here to find out more).
For alternative payment options and delivery methods, or other questions, please send an email to email@example.com.